Although the results of hypothesis-generating small clinical studies or retrospective analyses in selected patient categories have been positive, larger prospective RCTs have yielded controversial, mostly negative, results.
The controversy exists on whether upstream therapy may impact mortality and major non-fatal cardiovascular events in patients with AF.